As I said in my presentation, is the PMPRB's role strictly to ensure that the price of patented medicines is not excessive, or is it a body that ensures access to medicines at a price that is not excessive? There's a big difference there.
To give you a short answer, please read the briefs presented during the last or second-last consultation period. Some briefs implied that imposing a price that was too low might have a very significant impact on access to medicines in Canada. That's why this part of the mandate needs to be looked at carefully, because it might be viewed very differently by parliamentarians or even by people at the PMPRB.